EPS for MannKind Corporation (MNKD) Expected At $-0.29

February 15, 2018 - By Richard Conner

 EPS for MannKind Corporation (MNKD) Expected At $ 0.29

Analysts expect MannKind Corporation (NASDAQ:MNKD) to report $-0.29 EPS on March, 15.They anticipate $0.10 EPS change or 52.63 % from last quarter’s $-0.19 EPS. After having $-0.31 EPS previously, MannKind Corporation’s analysts see -6.45 % EPS growth. The stock decreased 8.41% or $0.27 during the last trading session, reaching $2.94. About 5.13 million shares traded or 28.11% up from the average. MannKind Corporation (NASDAQ:MNKD) has declined 75.27% since February 15, 2017 and is downtrending. It has underperformed by 91.97% the S&P500.

MannKind Corporation (NASDAQ:MNKD) Ratings Coverage

Among 7 analysts covering Mannkind (NASDAQ:MNKD), 2 have Buy rating, 3 Sell and 2 Hold. Therefore 29% are positive. Mannkind had 15 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was downgraded by RBC Capital Markets on Wednesday, November 4 to “Underperform”. Piper Jaffray downgraded MannKind Corporation (NASDAQ:MNKD) on Wednesday, September 9 to “Underweight” rating. As per Wednesday, November 8, the company rating was maintained by H.C. Wainwright. The stock has “Underperform” rating by RBC Capital Markets on Tuesday, May 10. The firm earned “Underweight” rating on Wednesday, January 6 by Piper Jaffray. H.C. Wainwright maintained the shares of MNKD in report on Tuesday, October 24 with “Buy” rating. The stock of MannKind Corporation (NASDAQ:MNKD) earned “Buy” rating by Maxim Group on Friday, September 1. The company was downgraded on Friday, August 28 by Vetr. The stock has “Buy” rating by Maxim Group on Friday, August 11. The firm has “Underperform” rating by RBC Capital Markets given on Wednesday, January 6.

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. The company has market cap of $349.48 million. The Company’s approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. It currently has negative earnings.

More notable recent MannKind Corporation (NASDAQ:MNKD) news were published by: Seekingalpha.com which released: “MannKind – Afrezza Scripts Remain Flat As Company Hires New Executive” on February 10, 2018, also Fool.com with their article: “The Simple Reason Why I Won’t Buy MannKind Corporation Stock” published on January 18, 2018, Fool.com published: “Why MannKind Corporation Stock Is Falling Back to Earth Today” on January 26, 2018. More interesting news about MannKind Corporation (NASDAQ:MNKD) were released by: Fool.com and their article: “The Most Likely Reason Why MannKind Corporation Skyrocketed Higher Today” published on January 25, 2018 as well as Investorplace.com‘s news article titled: “Don’t Buy MannKind Corporation Stock Under Any Circumstances” with publication date: February 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.